CARDIORENAL METABOLIC SYNDROME.
NOVAPEP IS MODIFYING NVP-202 TO PRODUCE NOVEL PEPTIDE ANALOGS WITH SIGNIFICANTLY IMPROVED CIRCULATING HALF-LIFE - THE NVP-300 SERIES.
NVP-300 Series Lead Candidate in Diabetic Cardiorenal Syndrome
The Lead NVP-300 Candidate will be progressed into a Phase 1 Trial in 2027.
COLITIS PROGRAM
APC has been shown to be effective in vivo in diabetic kidney disease and diabetes-induced atherosclerosis:
-
'Activated Protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.' Isermann et al, Nature Medicine, 2007.
-
Activated Protein C Targets PI3K-p85/XBP1 Pathway to Inhibit Hyperglycemia Induced Endoplasmic Reticulum Stress in Diabetic Nephropathy.' Isermann et al, Blood, 2012.
-
'Integrin Alphav-beta3 on Podocytes Orchestrates Coagulation Protease Signaling through Protease-Activated Receptors'. Madhusudhan et al, Blood, 2017
-
‘Diabetic kidney disease: as easy as aPC?’ MacFadyen et al, Blood, 2017.
-
Cytoprotective Activated Protein C averts Nlrp3 inflammasome induced ischemia-reperfusion injury via mTORC1 inhibition.’ Nazir et al, Blood, 2017.
-
'Reversal of the renal hyperglycemic memory in diabetic kidney disease by targeting sustained tubular P21 expression.' Al-Dabet et al. Nature Coms, 2022.
-
'Activated protein C ameliorates diabetes-induced atherosclerosis by sustaining macrophage efferocytosis.' Ambreen et al. Cardiovasc Diabetol, 2025.